Beam Therapeutics Posts $1.28 Per-Share Loss for Third Quarter
BEAM sits 28% above its 52-week low of $20.23.
Summary
Beam reported a third-quarter loss of $1.28 per share, per Dow Jones Newswires, wider than analysts expected as revenue dropped. That follows a $122.7M net loss in Q2, when the company held $1.2B in cash; the company ended 3Q 2026 with $1B in cash, cash equivalents and marketable securities, and its cash runway is expected to support operating plans into mid-2029. The stock sits at $25.87 after a rough stretch: shares fell 9% to $26.88 on September 8 when updated BEAM-302 AATD data showed total AAT levels declining, and the September 8 release had already framed BEAM-302 pivotal dosing and BEAM-304 IND clearance as the next clinical milestones. The wider-than-expected loss puts more pressure on a name already trading below its post-data level. Watch the BEAM-302 pivotal dosing update and BEAM-304 IND clearance as the events that decide the story from here.
At the time of this announcement, BEAM was trading at $25.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $20.23 to $38.26. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.